Review



mlif elisa kit  (R&D Systems)


Bioz Verified Symbol R&D Systems is a verified supplier
Bioz Manufacturer Symbol R&D Systems manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 94
      Buy from Supplier

    Structured Review

    R&D Systems mlif elisa kit
    (A) lif expression in the scRNA-seq from mouse livers with acetaminophen (APAP)-induced injury at the indicated time points. (B) lif expression in the scRNA-seq across cell types in the livers of mouse with APAP injury at the indicated time points. (C) lif expression in spatial transcriptomics of liver samples from healthy (HEA2) and APAP injury (APAP1_S2) humans. (D&E) Serum <t>mLIF</t> levels at 24, 48, and 72 h after partial hepatectomy (PHx) in mice treated with IgG (D) or anti-LIF neutralizing antibody (E). (F) Resected liver-to-body weight ratio in mice treated with anti-LIF antibody or control IgG. (G) Liver-to-body weight ratio at 24, 48, 72 h and 1-week post-PHx in mice treated with anti-LIF antibody or control IgG. (H) Immunofluorescence staining of liver sections at 48 h post-PHx from mice treated with anti-LIF antibody or control IgG. DAPI (blue), PCNA (red), CK19 (purple). Scale bars: 100 μm. (I) Quantification of PCNA-positive hepatocytes ratio at 48 h post-PHx in mice treated with anti-LIF antibody or control IgG.
    Mlif Elisa Kit, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 34 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mlif+elisa+kit/bio_rxiv__64898__2026__02__24__707802-245-12-15?v=R%26D+Systems
    Average 94 stars, based on 34 article reviews
    mlif elisa kit - by Bioz Stars, 2026-07
    94/100 stars

    Images

    1) Product Images from "The LIF-LIFR Axis Promotes Liver Regeneration via Modulation of Angiogenesis and HGF Release from LSECs"

    Article Title: The LIF-LIFR Axis Promotes Liver Regeneration via Modulation of Angiogenesis and HGF Release from LSECs

    Journal: bioRxiv

    doi: 10.64898/2026.02.24.707802

    (A) lif expression in the scRNA-seq from mouse livers with acetaminophen (APAP)-induced injury at the indicated time points. (B) lif expression in the scRNA-seq across cell types in the livers of mouse with APAP injury at the indicated time points. (C) lif expression in spatial transcriptomics of liver samples from healthy (HEA2) and APAP injury (APAP1_S2) humans. (D&E) Serum mLIF levels at 24, 48, and 72 h after partial hepatectomy (PHx) in mice treated with IgG (D) or anti-LIF neutralizing antibody (E). (F) Resected liver-to-body weight ratio in mice treated with anti-LIF antibody or control IgG. (G) Liver-to-body weight ratio at 24, 48, 72 h and 1-week post-PHx in mice treated with anti-LIF antibody or control IgG. (H) Immunofluorescence staining of liver sections at 48 h post-PHx from mice treated with anti-LIF antibody or control IgG. DAPI (blue), PCNA (red), CK19 (purple). Scale bars: 100 μm. (I) Quantification of PCNA-positive hepatocytes ratio at 48 h post-PHx in mice treated with anti-LIF antibody or control IgG.
    Figure Legend Snippet: (A) lif expression in the scRNA-seq from mouse livers with acetaminophen (APAP)-induced injury at the indicated time points. (B) lif expression in the scRNA-seq across cell types in the livers of mouse with APAP injury at the indicated time points. (C) lif expression in spatial transcriptomics of liver samples from healthy (HEA2) and APAP injury (APAP1_S2) humans. (D&E) Serum mLIF levels at 24, 48, and 72 h after partial hepatectomy (PHx) in mice treated with IgG (D) or anti-LIF neutralizing antibody (E). (F) Resected liver-to-body weight ratio in mice treated with anti-LIF antibody or control IgG. (G) Liver-to-body weight ratio at 24, 48, 72 h and 1-week post-PHx in mice treated with anti-LIF antibody or control IgG. (H) Immunofluorescence staining of liver sections at 48 h post-PHx from mice treated with anti-LIF antibody or control IgG. DAPI (blue), PCNA (red), CK19 (purple). Scale bars: 100 μm. (I) Quantification of PCNA-positive hepatocytes ratio at 48 h post-PHx in mice treated with anti-LIF antibody or control IgG.

    Techniques Used: Expressing, Spatial Transcriptomics, Control, Immunofluorescence, Staining

    (A-C) Body weight (A), liver weight (B) and liver-to-body weight ratio (C) of mice injected with AAV8-TBG-mLIF at the indicated titers. (D) Serum mLIF levels in mice injected with AAV8-TBG-mLIF at the indicated titers. (E&F) CD31 immunofluorescence staining of liver sections from mice injected with low-doses AAV8-TBG-mLIF (1×10⁸ or 2.5×10⁸ GC/mouse) (E) and quantified in (F). Scale bar=50 μm. (G) Serum HGF levels in mice injected with AAV8-TBG-mLIF at the indicated titers. (H) Liver-to-body weight ratio at the indicated time points post-PHx in mice injected with low-doses AAV8-TBG-mLIF (1×10⁸ or 2.5×10⁸ GC/mouse). (I&J) Serum mLIF (H) and HGF (I) levels at 24, 48 and 72 h post-PHx in mice injected with low-doses AAV8-TBG-mLIF (1×10⁸ or 2.5×10⁸ GC/mouse).
    Figure Legend Snippet: (A-C) Body weight (A), liver weight (B) and liver-to-body weight ratio (C) of mice injected with AAV8-TBG-mLIF at the indicated titers. (D) Serum mLIF levels in mice injected with AAV8-TBG-mLIF at the indicated titers. (E&F) CD31 immunofluorescence staining of liver sections from mice injected with low-doses AAV8-TBG-mLIF (1×10⁸ or 2.5×10⁸ GC/mouse) (E) and quantified in (F). Scale bar=50 μm. (G) Serum HGF levels in mice injected with AAV8-TBG-mLIF at the indicated titers. (H) Liver-to-body weight ratio at the indicated time points post-PHx in mice injected with low-doses AAV8-TBG-mLIF (1×10⁸ or 2.5×10⁸ GC/mouse). (I&J) Serum mLIF (H) and HGF (I) levels at 24, 48 and 72 h post-PHx in mice injected with low-doses AAV8-TBG-mLIF (1×10⁸ or 2.5×10⁸ GC/mouse).

    Techniques Used: Injection, Immunofluorescence, Staining



    Similar Products

    mlif elisa kit  (R&D Systems)
    94
    R&D Systems mlif elisa kit
    (A) lif expression in the scRNA-seq from mouse livers with acetaminophen (APAP)-induced injury at the indicated time points. (B) lif expression in the scRNA-seq across cell types in the livers of mouse with APAP injury at the indicated time points. (C) lif expression in spatial transcriptomics of liver samples from healthy (HEA2) and APAP injury (APAP1_S2) humans. (D&E) Serum <t>mLIF</t> levels at 24, 48, and 72 h after partial hepatectomy (PHx) in mice treated with IgG (D) or anti-LIF neutralizing antibody (E). (F) Resected liver-to-body weight ratio in mice treated with anti-LIF antibody or control IgG. (G) Liver-to-body weight ratio at 24, 48, 72 h and 1-week post-PHx in mice treated with anti-LIF antibody or control IgG. (H) Immunofluorescence staining of liver sections at 48 h post-PHx from mice treated with anti-LIF antibody or control IgG. DAPI (blue), PCNA (red), CK19 (purple). Scale bars: 100 μm. (I) Quantification of PCNA-positive hepatocytes ratio at 48 h post-PHx in mice treated with anti-LIF antibody or control IgG.
    Mlif Elisa Kit, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/mlif+elisa+kit/bio_rxiv__64898__2026__02__24__707802-245-12-15?v=R%26D+Systems
    Average 94 stars, based on 1 article reviews
    mlif elisa kit - by Bioz Stars, 2026-07
    94/100 stars
    		  Buy from Supplier

    Image Search Results


    (A) lif expression in the scRNA-seq from mouse livers with acetaminophen (APAP)-induced injury at the indicated time points. (B) lif expression in the scRNA-seq across cell types in the livers of mouse with APAP injury at the indicated time points. (C) lif expression in spatial transcriptomics of liver samples from healthy (HEA2) and APAP injury (APAP1_S2) humans. (D&E) Serum mLIF levels at 24, 48, and 72 h after partial hepatectomy (PHx) in mice treated with IgG (D) or anti-LIF neutralizing antibody (E). (F) Resected liver-to-body weight ratio in mice treated with anti-LIF antibody or control IgG. (G) Liver-to-body weight ratio at 24, 48, 72 h and 1-week post-PHx in mice treated with anti-LIF antibody or control IgG. (H) Immunofluorescence staining of liver sections at 48 h post-PHx from mice treated with anti-LIF antibody or control IgG. DAPI (blue), PCNA (red), CK19 (purple). Scale bars: 100 μm. (I) Quantification of PCNA-positive hepatocytes ratio at 48 h post-PHx in mice treated with anti-LIF antibody or control IgG.

    Journal: bioRxiv

    Article Title: The LIF-LIFR Axis Promotes Liver Regeneration via Modulation of Angiogenesis and HGF Release from LSECs

    doi: 10.64898/2026.02.24.707802

    Figure Lengend Snippet: (A) lif expression in the scRNA-seq from mouse livers with acetaminophen (APAP)-induced injury at the indicated time points. (B) lif expression in the scRNA-seq across cell types in the livers of mouse with APAP injury at the indicated time points. (C) lif expression in spatial transcriptomics of liver samples from healthy (HEA2) and APAP injury (APAP1_S2) humans. (D&E) Serum mLIF levels at 24, 48, and 72 h after partial hepatectomy (PHx) in mice treated with IgG (D) or anti-LIF neutralizing antibody (E). (F) Resected liver-to-body weight ratio in mice treated with anti-LIF antibody or control IgG. (G) Liver-to-body weight ratio at 24, 48, 72 h and 1-week post-PHx in mice treated with anti-LIF antibody or control IgG. (H) Immunofluorescence staining of liver sections at 48 h post-PHx from mice treated with anti-LIF antibody or control IgG. DAPI (blue), PCNA (red), CK19 (purple). Scale bars: 100 μm. (I) Quantification of PCNA-positive hepatocytes ratio at 48 h post-PHx in mice treated with anti-LIF antibody or control IgG.

    Article Snippet: The following steps were carried out according to the manufacturer’s protocols from mLIF ELISA kit (R&D system, MLF00).

    Techniques: Expressing, Spatial Transcriptomics, Control, Immunofluorescence, Staining

    (A-C) Body weight (A), liver weight (B) and liver-to-body weight ratio (C) of mice injected with AAV8-TBG-mLIF at the indicated titers. (D) Serum mLIF levels in mice injected with AAV8-TBG-mLIF at the indicated titers. (E&F) CD31 immunofluorescence staining of liver sections from mice injected with low-doses AAV8-TBG-mLIF (1×10⁸ or 2.5×10⁸ GC/mouse) (E) and quantified in (F). Scale bar=50 μm. (G) Serum HGF levels in mice injected with AAV8-TBG-mLIF at the indicated titers. (H) Liver-to-body weight ratio at the indicated time points post-PHx in mice injected with low-doses AAV8-TBG-mLIF (1×10⁸ or 2.5×10⁸ GC/mouse). (I&J) Serum mLIF (H) and HGF (I) levels at 24, 48 and 72 h post-PHx in mice injected with low-doses AAV8-TBG-mLIF (1×10⁸ or 2.5×10⁸ GC/mouse).

    Journal: bioRxiv

    Article Title: The LIF-LIFR Axis Promotes Liver Regeneration via Modulation of Angiogenesis and HGF Release from LSECs

    doi: 10.64898/2026.02.24.707802

    Figure Lengend Snippet: (A-C) Body weight (A), liver weight (B) and liver-to-body weight ratio (C) of mice injected with AAV8-TBG-mLIF at the indicated titers. (D) Serum mLIF levels in mice injected with AAV8-TBG-mLIF at the indicated titers. (E&F) CD31 immunofluorescence staining of liver sections from mice injected with low-doses AAV8-TBG-mLIF (1×10⁸ or 2.5×10⁸ GC/mouse) (E) and quantified in (F). Scale bar=50 μm. (G) Serum HGF levels in mice injected with AAV8-TBG-mLIF at the indicated titers. (H) Liver-to-body weight ratio at the indicated time points post-PHx in mice injected with low-doses AAV8-TBG-mLIF (1×10⁸ or 2.5×10⁸ GC/mouse). (I&J) Serum mLIF (H) and HGF (I) levels at 24, 48 and 72 h post-PHx in mice injected with low-doses AAV8-TBG-mLIF (1×10⁸ or 2.5×10⁸ GC/mouse).

    Article Snippet: The following steps were carried out according to the manufacturer’s protocols from mLIF ELISA kit (R&D system, MLF00).

    Techniques: Injection, Immunofluorescence, Staining